CytoSorbents Reports Preliminary 2019 Financial Results and Issues Stockholder Letter Growth accelerated in Q4 2019, with preliminary record total revenue of $7.4 million and record product sales of $6.6 million, driven

CytoSorbents Reports Preliminary 2019

Financial Results and Issues Stockholder Letter

Growth accelerated in Q4 2019, with preliminary

record total revenue of $7.4 million and record product sales of $6.6 million, driven by a 30% increase in direct sales. Cumulative

CytoSorb treatments surpassed 80,000

MONMOUTH JUNCTION, NJ - January

14, 2019 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb

blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world,

issues a stockholder letter from Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, and pre-announces preliminary unaudited

fourth quarter 2019 and full-year 2019 results ahead of filing its Form 10-K.

Preliminary 2019 Financial Highlights:

The Company expects to announce the

Dear Stockholders and Friends,

First, let me thank all of you for your

patience and support in 2019, which was a challenging year. It was technically our best year ever, but clearly did not meet our

collective expectations. We disappointed you, and as a stockholder myself, I understand and share your disappointment.

That said, as we say goodbye to 2019, and

warmly welcome the new decade, we ended the year on a strong note, with a 21% resurgence in growth and achievement of preliminary,

unaudited record Q4 2019 total revenue and product sales of $7.4 million and $6.6 million, respectively. And despite the growing

pains, 2019 was still a year of progress.

For 2020, our focus will be to drive our

U.S. and E.U. clinical programs and maximize sales.

I have personally taken over the role of

interim Chief Medical Officer for the time being, acknowledging with utmost importance the priority and urgency of our clinical

programs. This is being done in parallel to an aggressive search for a new CMO. As we work to resume the REFRESH 2-AKI trial, we

believe the anti-thrombotic removal application for cardiac surgery represents a potentially rapid, relatively inexpensive pathway

for U.S. FDA approval and are aggressively pursuing this strategy. Meanwhile the U.S. and E.U. clinical teams are working together

to advance the U.K. TISORB study and initiate new company-sponsored critical care and cardiac surgery studies in the E.U.

From a commercialization standpoint, the

company is much stronger than it was a year ago, with more people and expertise than we have ever had. For example, we have substantially

expanded our sales and marketing resources in Europe and elsewhere, such that for the first time, the commercialization team is

now approximately the size of our U.S. operations. Importantly, we have more than doubled the number of customer facing sales representatives

and specialists in Germany - our core market that accounts for 60-65% of our product sales. This increase in headcount is intended

to allow our sales people to be more efficient, to better serve our customers, to communicate the value proposition of CytoSorb

more effectively, and to harvest sales. In addition, we have added significant resources to better optimize our sales processes,

take advantage of new clinical applications, and strengthen our marketing messaging. Meanwhile, distributor and partner sales are

expected to increase as well, aided by recent clinical successes, new clinical data and applications, select reimbursement, and

multiple expected registration approvals in Latin America. This also includes Mexico registration that is anticipated to accelerate

our partnership with Fresenius Medical Care.

We believe our business has never been

as exciting as it is today. Unlike products that address a single problem, CytoSorb is riding the wave of multiple macro trends

in healthcare. The aging baby boomer generation is driving the incidence of serious infections and sepsis, trauma, the use of blood

thinners to prevent strokes and heart attacks, sudden cardiac arrest, and cardiac surgery for both coronary artery disease and

structural heart disease. The chronic liver disease pandemic that afflicts 1 in 11 people worldwide, results in millions of people

being admitted to hospitals for acute exacerbations of their disease each year, where CytoSorb is viewed by some as the next generation

liver support therapy. The advent of cancer immunotherapy has significantly increased the risk of associated adverse events such

as cytokine release syndrome and infection that CytoSorb was designed to treat. The opiate crisis and use of dirty needles has

resulted in a devastating burden of critically-ill patients with infective endocarditis, sepsis and acute heart failure, where

CytoSorb is being used to stabilize patients both intraoperatively and postoperatively. And last, but not least, critical care

is a crushing economic burden on hospitals and healthcare systems due to the lack of effective therapies to treat patients. CytoSorb

represents a paradigm shift in the treatment of critically-ill patients and may dramatically improve the economics of ICU care.

But what makes it all worthwhile is knowing

that CytoSorb is being used to help save lives around the world. Whether it was the real-world case of a young pregnant woman who

held her baby in her arms just hours after surviving complicated emergency surgeries to deliver her unborn baby by cesarean section

and then repair her rupturing aorta under the protectiion of CytoSorb. Or the grandfather who will be there for his grandchildren

after being rescued from massive organ failure and septic shock with CytoSorb following surgery for colon cancer. Or the young

man who collapsed to the ground in cardiac arrest, underwent nearly 2 hours of CPR in the field, followed by extracorporeal CPR

and CytoSorb, and walked out of the hospital 2 weeks later, doing well without significant brain damage. These are real-life examples

of how physicians are using our CytoSorb therapy to make a positive difference in the lives of patients and their families.

We start the New Year confident that we

have the right product, the right strategy, and most importantly the right people to make this company successful. We would like

to thank all of you in the extended CytoSorbents family who have given your time, energy, hard work, expertise, trust, and support

to help establish CytoSorb as a key therapeutic option for those in greatest need. Without you, none of this would be possible.

To the patients and their families, physicians, nurses, healthcare workers, hospital leadership and administrators, scientific

and clinical researchers, distributors, strategic partners, service providers, shareholders and especially our employees and their

families.. On behalf of the Board of Directors and the management team, we are grateful to all of you for helping to make

this a reality and for continuing to share this journey with us! Our best wishes to you and your loved ones for a healthy, happy,

and successful New Year!

Dr. Phillip Chan, MD, PhD

Chief Executive Officer

CytoSorbents Corporation

About CytoSorbents Corporation (NASDAQ: CTSO)

Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb

is approved in the European Union with distribution in 58 countries around the world, as an extracorporeal cytokine

adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause

massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely

high, yet no effective treatments exist. CytoSorb

is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications,

including multiple organ failure. CytoSorbents is conducting its pivotal REFRESH 2-AKI trial - a multi-center, randomized

controlled, clinical trial intended to support U.S. regulatory approval of CytoSorb for use in a heart-lung machine during complex

cardiac surgery to reduce organ injury. The Company has also initiated the company-sponsored

U.K. TISORB trial evaluating the removal of ticagrelor in emergency cardiac surgery patients. CytoSorb

has been used in more than 80,000 human treatments to date.

purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from

blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract,

and other funding of approximately $29 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services,

the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM),

and others. The Company has numerous products under development based upon this unique blood purification technology protected

by many issued U.S. and international patents and multiple applications pending, including CytoSorb-XL , HemoDefend ,

VetResQ , K+ontrol , ContrastSorb, DrugSorb, and others. For

more information, please visit the Company's websites at www.cytosorbents.com

Forward-Looking Statements

This press release includes forward-looking

statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of

1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations

and contentions and are not historical facts and typically are identified by use of terms such as "may," "should,"

"could," "expect," "plan," "anticipate," "believe," "estimate,"

"predict," "potential," "continue" and similar words, although some forward-looking statements

are expressed differently. You should be aware that the forward-looking statements in this press release represent management's

current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking